Myelodysplastic and Myeloproliferative Disorders
Myelodysplastic and myeloproliferative disorders are clonal diseases of the bone marrow stem cell, in which an acquired genetic lesion drives abnormal production of one or more blood cell lineages. The two faces of this group are dysplasia with ineffective production and cytopenias (myelodysplastic syndromes) and effective overproduction of mature cells (myeloproliferative neoplasms); the World Health Organization classifies both, along with overlap forms, as myeloid neoplasms.
Definition
Myelodysplastic and myeloproliferative disorders are clonal hematopoietic stem-cell neoplasms classified by the World Health Organization, characterized either by morphologic dysplasia with ineffective hematopoiesis and peripheral cytopenias, or by sustained overproduction of one or more mature myeloid lineages, or by overlapping features of both.
Scope
This area orients the reader to the shared biology and clinical logic of clonal myeloid disorders and links to detailed topic entries: myelodysplastic syndromes, the classic Philadelphia-chromosome-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis), and the diagnostic workup of cytopenias and bone marrow. It is a reference and educational overview of disease concepts, not clinical management guidance.
Sub-topics
Key concepts
- Clonal hematopoiesis
- Ineffective hematopoiesis (dysplasia)
- Effective overproduction (myeloproliferation)
- Driver mutations (JAK2, CALR, MPL; splicing and epigenetic genes)
- Risk of leukemic transformation
- WHO classification of myeloid neoplasms
- Prognostic scoring systems
Mechanisms
Both families begin when a single hematopoietic stem cell acquires a somatic mutation that gives it a growth or survival advantage, producing a clone. In the myeloproliferative neoplasms, mutations that activate cytokine signalling, most often JAK2 V617F and less commonly CALR or MPL mutations, drive constitutive proliferation of erythroid, megakaryocytic, or granulocytic lineages (Kralovics, 2005). In the myelodysplastic syndromes, mutations in splicing, epigenetic, and transcription factor genes lead to dysplastic, ineffective maturation so that cells are produced but die before reaching the circulation, causing cytopenias despite a cellular marrow. The WHO frames these as a continuum of myeloid neoplasia in which clones may acquire further lesions and progress, in some cases toward acute myeloid leukemia (Arber, 2016; Khoury, 2022).
Clinical relevance
Clonal myeloid disorders explain a large share of unexplained anemia, erythrocytosis, thrombocytosis, and marrow fibrosis encountered in adults, and understanding their shared and divergent biology informs how clinicians interpret blood counts and marrow findings. This entry describes disease concepts and classification for reference; it does not provide diagnostic thresholds or treatment recommendations for individual patients.
Epidemiology
These are predominantly diseases of older adults, with incidence rising markedly with age. The myelodysplastic syndromes and the classic myeloproliferative neoplasms each occur on the order of a few cases per hundred thousand people per year, and their precursor state, clonal hematopoiesis, becomes common in later life. Precise rates vary by entity and are addressed in the individual topic entries.
History
The conceptual unification of these disorders advanced through successive classifications. William Dameshek in 1951 proposed grouping the myeloproliferative diseases by their shared overproduction. The French-American-British group later formalized the myelodysplastic syndromes by morphology, and the World Health Organization then integrated morphology with genetics into a single scheme of myeloid neoplasms, revised in 2016 and again in 2022 (Arber, 2016; Khoury, 2022). The 2005 discovery of the JAK2 V617F mutation provided a unifying molecular basis for the classic myeloproliferative neoplasms (Kralovics, 2005).
Key figures
- Robert Kralovics
- Radek Skoda
- Daniel Arber
- James Vardiman
- Mario Cazzola
Related topics
Seminal works
- arber-2016
- kralovics-2005
- khoury-2022
Frequently asked questions
- What distinguishes myelodysplastic syndromes from myeloproliferative neoplasms?
- Both are clonal stem-cell disorders, but myelodysplastic syndromes feature dysplastic, ineffective production with low blood counts, whereas myeloproliferative neoplasms feature effective overproduction of mature cells. Some overlap conditions show features of both.
- Are these disorders cancers?
- The World Health Organization classifies them as myeloid neoplasms, that is, clonal malignancies of the bone marrow, even though their behaviour ranges from indolent to rapidly progressive.